Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04232280 · ClinicalTrials.gov registry record · Phase 2
Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
A Phase 2 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 2
- Development phase
- 315
- Enrollment target
NCT04232280 is a Phase 2 study that has completed, run by ModernaTX. The registered enrollment target is 315 participants.
The verdict
NCT04232280, a Phase 2 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 315 participants
- Enrollment target
Study Summary
This clinical study will assess the safety and immunogenicity of 3 dose levels of mRNA-1647 cytomegalovirus vaccine in CMV-seronegative and CMV-seropositive healthy adults 18-40 years of age.
Interventions
- OTHER Placebo
- BIOLOGICAL mRNA-1647
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2020-01-09 |
| Est. Completion | 2023-01-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04232280
The ClinicalTrials.gov registry entry for NCT04232280 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 315 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04232280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04232280 about?
NCT04232280 is a clinical study titled "Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults". This clinical study will assess the safety and immunogenicity of 3 dose levels of mRNA-1647 cytomegalovirus vaccine in CMV-seronegative and CMV-seropositive healthy adults 18-40 years of age.
What is the current status of trial NCT04232280?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 315 participants. The study started on 2020-01-09. Estimated completion is 2023-01-04.
What interventions are being tested in trial NCT04232280?
The interventions under investigation include: Placebo (OTHER), mRNA-1647 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04232280?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.